natgillin/translations-raw huggingface dataset:
TachoSil comes ready to use in sterile packages and must be handled accordingly.
TachoSil je pripravljen za uporabo v sterilni ovojnini in je treba z njim ustrezno ravnati.
Use only undamaged packages.
Uporabite samo nepoškodovana pakiranja.
Once the package is opened post-sterilisation is not possible. The outer aluminium foil sachet may be opened in a non-sterile operating area.
Zunanja vrečka iz aluminijaste folije se lahko odpre v nesterilnih pogojih.
The inner sterile blister must be opened in a sterile operating room area.
Stični sterilni pretisni omot se lahko odpira samo v sterilnih pogojih.
TachoSil should be used immediately after opening the inner sterile cover.
TachoSil je potrebno uporabiti takoj po odprtju stične sterilne ovojnine.
TachoSil is used under sterile conditions.
TachoSil se uporablja v sterilnih pogojih.
Prior to application the wound area should be cleansed, e. g. from blood, disinfectants and other fluids.
Pred namestitvijo mora biti površina rane očiščena, npr. krvi, razkužil in drugih tekočin.
After removal of TachoSil from the sterile package the sponge should be pre-moistened in saline solution and then applied immediately.
Potem ko TachoSil gobico vzamete iz sterilne ovojnine, jo morate predhodno navlažiti v fiziološki raztopini in nato takoj namestiti.
The yellow, active side of the sponge is applied to the bleeding/ leaking surface and held against it with a gentle pressure for 3-5 minutes.
Rumeno, učinkovito stran gobice namestite na krvavečo/ prepuščajočo površino in jo nanjo nežno pritiskajte za 3- 5 minut.
This procedure enables an easy adhesion of TachoSil to the wound surface.
Ta postopek omogoča, da se TachoSil zlahka sprime s površino rane.
Pressure is applied with moistened gloves or a moist pad.
Pritisk izvršite z navlaženimi rokavicami ali vlažno blazinico.
Due to the strong affinity of collagen to blood, TachoSil may also stick to surgical instruments or gloves covered with blood.
Zaradi močne afinitete kolagena do krvi se TachoSil lahko prime tudi na kirurške instrumente ali rokavice, na katerih je kri.
This can be avoided by pre-moistening surgical instruments and gloves with physiological saline solution.
Temu se lahko izognete s slano fiziološko raztopino predhodno navlaženimi kirurškimi instrumenti in rokavicami.
After pressing TachoSil to the wound, the glove or the pad must be removed carefully.
Po pritrditvi TachoSila na rano je treba rokavico ali blazinico pazljivo odstraniti.
To avoid the sponge from being pulled loose it may be held in place at one end, e. g. with a pair of forceps.
Gobico lahko držimo na mestu na enem koncu, npr. s parom klešč, zato da je ne potegnemo z rane.
Alternatively, e. g. in case of stronger bleeding, TachoSil may be applied without pre-moistening, while also pressing gently to the wound for 3-5 minutes.
Alternativno, npr. pri močnejši krvavitvi, lahko TachoSil namestite brez predhodne navlažitve, medtem ko nežno pritiskate na rano za 3- 5 minut.
The TachoSil sponge should be applied so that it extends 1-2 cm beyond the margins of the wound.
Gobico TachoSil namestite tako, da sega od 1- 2 cm preko robov rane.
If more than one sponge is used the sponges should overlap.
Če uporabite več kot eno gobico, se morajo gobice prekrivati.
The sponge can be cut to the correct size and shaped if too large.
Če je gobica prevelika, jo lahko obrežete in oblikujete na ustrezno velikost.
8 A MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCES AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
IZDELOVALCI BIOLOŠKIH ZDRAVILNIH UČINKOVIN IN IMETNIK DOVOLJENJA ZA IZDELAVO ZDRAVILA, ODGOVOREN ZA SPROŠČANJE SERIJE
Box 1230 D-35002 Marburg/ Lahn Germany
Box 1230 D- 35002 Marburg/ Lahn Nemčija
Peter Strasse 25 A-4020 Linz Austria
Peter Strasse 25 A- 4020 Linz Avstrija
Risk Management Plan The MAH commits to performing the studies and additional pharmacovigilance activities detailed in the Pharmacovigilance Plan, as agreed in version 3.0 of the Risk Management Plan (RMP) presented in Module 1.8.2. of the Marketing Authorisation Application and any subsequent updates of the RMP agreed by the CHMP.
Načrt za obvladovanje tveganja Imetnik dovoljenja za promet z zdravilom se zavezuje, da bo izvedel študije in dodatne dejavnosti farmakovigilance, ki so navedene v načrtu farmakovigilance, kot je bilo dogovorjeno v različici 3. 0 Načrta za obvladovanje tveganja (RMP – » Risk Management Plan «), predstavljenem v Modulu 1. 8. 2. vloge za pridobitev dovoljenja za promet z zdravilom in vseh nadaljnjih posodobitvah RMP, s katerimi soglaša Odbor za zdravila za uporabo v humani medicini (CHMP).
As per the CHMP Guideline on Risk Management Systems for medicinal products for human use, the updated RMP should be submitted at the same time as the next Periodic Safety Update Report (PSUR).
Sočasno z naslednjim rednim dopolnjenim poročilom o varnosti zdravila (PSUR) je treba predložiti dopolnjen Načrt za obvladovanje tveganja v skladu s Smernicami za sisteme obvladovanja tveganja pri zdravilih za uporabo v humani medicini Odbora za zdravila za uporabo v humani medicini (CHMP).
In addition, an updated RMP should be submitted • When new information is received that may impact on the current Safety Specification, Pharmacovigilance Plan or risk minimisation activities • Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached • At the request of the EMEA
Poleg tega je treba posodobljen RMP predložiti: • kadar imetnik dovoljenja za promet z zdravilom prejme nove informacije, ki lahko vplivajo na trenutne specifikacije varnosti zdravila, načrt farmakovigilance ali na dejavnosti za zmanjševanje tveganja • v 60 dneh po doseženem pomembnem mejniku (pri farmakovigilanci ali zmanjševanju tveganja) • na zahtevo Evropske agencije za zdravila (EMEA).
9 ANNEX III
9 10 DODATEK III
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
12 PODATKI NA ZUNANJI OVOJNINI
CARDBOARD BOX
KARTONASTA ŠKATLA
TachoSil, medicated sponge
TachoSil zdravilna gobica
Per cm2 Human fibrinogen 5.5 mg Human thrombin 2.0 IU
Na cm2 humani fibrinogen 5, 5 mg humani trombin 2, 0 i. e.
Equine collagen, human albumin, riboflavine (E101), sodium chloride, sodium citrate, L-arginin- hydrochloride
Konjski kolagen, humani albumin, riboflavin (E101), natrijev klorid, natrijev citrat, L- argininijev klorid
Medicated sponge 1 sponge of 9.5 cm x 4.8 cm 2 sponges of 4.8 cm x 4.8 cm 1 sponge of 3.0 cm x 2.5 cm 5 sponges of 3.0 cm x 2.5 cm
Zdravilna gobica 1 gobica velikosti 9, 5 cm x 4, 8 cm 2 gobici velikosti 4, 8 cm x 4, 8 cm 1 gobica velikosti 3, 0 cm x 2, 5 cm 5 gobic velikosti 3, 0 cm x 2, 5 cm
For local use Read the package leaflet before use.
Pred uporabo preberite priloženo navodilo.
Once the foil sachet is opened, use immediately.
Uporabite takoj po odprtju folijske vrečke.
NYCOMED Austria GmbH St. Peter Strasse 25 A- 4020 Linz, Austria
NYCOMED Austria GmbH St. Peter Strasse 25 A - 4020 Linz, Avstrija
EU/ 1/ 04/ 277/ 001 1 sponge of 9.5 cm x 4.8 cm EU/ 1/ 04/ 277/ 002 2 sponges of 4.8 cm x 4.8 cm EU/ 1/ 04/ 277/ 003 1 sponge of 3.0 cm x 2.5 cm EU/ 1/ 04/ 277/ 004 5 sponges of 3.0 cm x 2.5 cm
EU/ 1/ 04/ 277/ 001 1 gobica velikosti 9, 5 cm x 4, 8 cm EU/ 1/ 04/ 277/ 002 2 gobici velikosti 4, 8 cm x 4, 8 cm EU/ 1/ 04/ 277/ 003 1 gobica velikosti 3, 0 cm x 2, 5 cm EU/ 1/ 04/ 277/ 004 5 gobic velikosti 3, 0 cm x 2, 5 cm
13 MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS
14 PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNEM OMOTU ALI DVOJNEM TRAKU
(primary packaging)
(primarna ovojnina)
14 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
15 PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH OVOJNINAH
LABEL ON THE ALUMINIUM FOIL (secondary packaging)
OZNAKA NA ALUMINIJASTI FOLIJI (sekundarna ovojnina)
TachoSil, medicated sponge For local use
TachoSil zdravilna gobica Za lokalno uporabo
1 sponge of 9.5 cm x 4.8 cm 1 sponge of 4.8 cm x 4.8 cm 1 sponge of 3.0 cm x 2.5 cm
1 gobica velikosti 9, 5 cm x 4, 8 cm 1 gobica velikosti 4, 8 cm x 4, 8 cm 1 gobica velikosti 3, 0 cm x 2, 5 cm
Keep this leaflet.
17 NAVODILO ZA UPORABO
- If you have any further questions, ask your doctor.
TachoSil, zdravilna gobica humani fibrinogen, humani trombin
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet,
Pred uporabo natančno preberite navodilo!
please tell your doctor.
Navodilo shranite.
What TachoSil is and what it is used for 2.
Kaj je zdravilo TachoSil in za kaj ga uporabljamo 2.
3.
Kaj morate vedeti, preden boste uporabili zdravilo TachoSil 3.
How to use TachoSil 4.
Kako uporabljati zdravilo TachoSil 4.
How to store TachoSil 6.
Shranjevanje zdravila TachoSil 6.
WHAT TACHOSIL IS AND WHAT IT IS USED FOR
KAJ JE ZDRAVILO TACHOSIL IN ZA KAJ GA UPORABLJAMO
How does TachoSil work?
Kako deluje TachoSil?
The yellow side of the TachoSil sponge contains the active components: fibrinogen and thrombin.
Rumena stran gobiceTachoSil vsebuje učinkoviti komponenti: fibrinogen in trombin.
The yellow side of the sponge is therefore the active side.
Rumena stran gobice je torej učinkovita stran.
When the sponge comes into contact with fluids (such as blood, lymph or saline solution) the fibrinogen and the thrombin are activated and form a fibrin network.
Ko gobica pride v stik s tekočinami (kot so kri, limfa ali fiziološka raztopina) se fibrinogen in trombin aktivirata in tvorita fibrinsko mrežo.
This means that the sponge sticks to the tissue surface, the blood coagulates (local haemostasis) and the tissue is sealed.
To pomeni, da se gobica prime na površino tkiva - kri koagulira (lokalna hemostaza) in tkivo se zapre.
In the body TachoSil will dissolve and disappears completely.
TachoSil bo v telesu razpadel in popolnoma izginil.
What is TachoSil used for?
Za kaj se uporablja TachoSil?
TachoSil is used during surgery to stop local bleeding (haemostasis) and to seal tissue surfaces on internal organs.
TachoSil se uporablja med kirurškimi posegi za zaustavljanje lokalne krvavitve (hemostaza) in za zatesnitev tkivnih površin na notranjih organih.
BEFORE TACHOSIL IS USED
KAJ MORATE VEDETI, PREDEN BOSTE UPORABILI ZDRAVILO TACHOSIL
Do not use TachoSil
Ne uporabljajte zdravila TachoSil
- if you are allergic (hypersensitive) to human fibrinogen, human thrombin or any of the other
- če ste alergični (preobčutljivi) na humani fibrinogen, humani trombin ali katerokoli sestavino
ingredients of TachoSil.
zdravila TachoSil.
Important information about some of the ingredients of TachoSil When medicines are made from human blood or plasma, certain measures are put in place to prevent infections being passed on to the patients.
Pomembne informacije o nekaterih sestavinah zdravila TachoSil Če so zdravila izdelana iz humane krvi ali plazme, se uvedejo določeni ukrepi, da se prepreči prenos okužb na bolnika.
These include careful selection of blood and plasma donors to make sure those at risk of carrying infections are excluded, and the testing of each donation and pools of plasma for signs of virus/ infections.
Ti ukrepi obsegajo skrbno izbiro darovalcev krvi in plazme za izključitev možnih prenašalcev okužb, ter pregledovanje posameznih darovanj in zbirov plazme na znake virusov/ okužb.
Manufacturers of these products also include steps in the processing of the blood or plasma that can inactivate or remove viruses.
Proizvajalci teh zdravil v postopke obdelave krvi prav tako vključujejo korake, ki lahko inaktivirajo ali odstranijo viruse.
Despite these measures, when medicines prepared from human blood or plasma are administered, the possibility of passing on infection cannot be totally excluded.
Kljub tem ukrepom pri uporabi zdravil, pripravljenih iz humane krvi ali plazme, ni mogoče povsem izključiti možnosti prenosa okužb.
17 The measures taken are considered effective for enveloped viruses such as human immunodeficiency virus (HIV), hepatitis B virus and hepatitis C virus, and for the non-enveloped hepatitis A virus.
Uvedeni ukrepi pa
The measures taken may be of limited value against non-enveloped viruses such as parvovirus B19.
18 imajo lahko le omejeno vrednost proti virusom brez ovojnice, kot je parvovirus B19.
Parvovirus B19 infection may be serious for pregnant woman (fetal infection) and for individuals whose immune system is depressed or who have some types of anaemia, (e. g. sickle cell disease or haemolytic anaemia).
Okužba s parvovirusom B19 lahko resno ogroža nosečnice (okužba ploda) in posameznike z oslabljenim imunskim sistemom ali z nekaterimi vrstami anemije (npr. srpastocelično anemijo ali hemolitično anemijo).
It is strongly recommended that when you receive TachoSil the name and batch number of the product are recorded at the hospital in order to maintain a record of the batches used.
Za vodenje evidence o uporabljenih serijah je zelo priporočljivo, da se vsakič ko prejmete TachoSil v bolnišnici zabeleži ime in serijska številka zdravila.
HOW TO USE TACHOSIL
KAKO UPORABLJATI ZDRAVILO TACHOSIL
The doctor treating you will administer TachoSil during surgery.
Zdravnik, ki vas zdravi, vam bo namestil TachoSil med kirurškim posegom.
The doctor will place the sponge on the internal organ to stop the bleeding or to seal the tissue.
Zdravnik bo za zaustavitev krvavitve in za zatesnitev tkiva namestil gobico na notranji organ.
During the following time the sponge will dissolve and disappear completely.
Nato bo gobica razpadla in popolnoma izginila.
Like all medicines, TachoSil can cause side effects although not everybody gets them.
Kot vsa zdravila ima lahko tudi zdravilo TachoSil neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
TachoSil is made on the basis of human blood.
TachoSil je izdelan na osnovi humane krvi.
All medicines based on human blood may uncommonly (In more than 1 in 1,000 patients, but less than 1 in 100) cause allergic reactions.
Vsa zdravila, ki so na osnovi humane krvi, lahko občasno (pri več kot 1 na 1000 bolnikov, toda manj kot 1 na 100) povzročajo alergijske reakcije.
The above allergic reactions may especially occur if TachoSil is used repeatedly or if you are allergic to any of the ingredients in TachoSil.
Takšne alergijske reakcije se pojavijo zlasti, če se TachoSil namešča večkrat ali če ste alergični na katerokoli sestavino v TachoSilu.
In rare cases you may produce antibodies against the active substances of TachoSil.
V redkih primerih lahko razvijete protitelesa na zdravilni učinkovini TachoSila.
You may experience fever when taking Tachosil.
Pri uporabi TachoSila se lahko pojavi zvišana telesna temperatura.
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor
Če katerikoli neželeni učinek postane resen ali če opazite katerikoli neželeni učinek, ki ni omenjen v tem navodilu, obvestite svojega zdravnika.
HOW TO STORE TACHOSIL
SHRANJEVANJE ZDRAVILA TACHOSIL
You will not be required to store this product.
Zdravila vam ne bo potrebno shranjevati.
- The active substances are human fibrinogen (5.5 mg per cm2) and human thrombin (2.0 IU per
Zdravilni učinkovini sta humani fibrinogen (5, 5 mg na cm2) in humani trombin (2, 0 i. e. na cm2). − − Pomožne snovi so konjski kolagen, humani albumin, riboflavin (E101), natrijev klorid, natrijev citrat, L- argininijev klorid.
sodium citrate and L-arginin-hydrochloride.
Izgled zdravila TachoSil in vsebina pakiranja
What TachoSil looks like and contents of the pack
TachoSil je kolagenska gobica, ki je na rumeni strani obložena s humanim fibrinogenom in humanim trombinom.
TachoSil is a sponge made of collagen, which is coated on the yellow side with human fibrinogen and human thrombin.
Velikosti pakiranj Zdravilo je na voljo v različnih velikostih v pakiranjih, ki vsebujejo do 5 gobic:
Pack sizes
Pakiranje z 1 gobico velikosti 9, 5 cm x 4, 8 cm
Package with 1 sponge of 9.5 cm x 4.8 cm Package with 2 sponges of 4.8 cm x 4.8 cm Package with 1 sponge of 3.0 cm x 2.5 cm Package with 5 sponges of 3.0 cm x 2.5 cm
19 Pakiranje z 2 gobicama velikosti 4, 8 cm x 4, 8 cm Pakiranje z 1 gobico velikosti 3, 0 cm x 2, 5 cm Pakiranje s 5 gobicami velikosti 3, 0 cm x 2, 5 cm
Peter Strasse 25 A-4020 Linz, Austria
Peter Strasse 25 A- 4020 Linz, Avstrija
19 Ελλάδα Nycomed Hellas S. A.
20 Ελλάδα Nycomed Hellas S. A.
20 This leaflet was last approved on {MM/ YYYY}
21 Navodilo je bilo odobreno {MM/ LLLL}
------------------------------------------------------------------------------------------------------------------------------- The following information is intended for medical or healthcare professionals only:
------------------------------------------------------------------------------------------------------------------------------- Naslednje informacije so namenjene samo zdravstvenemu osebju:
Read this before you open the package:
Preberite naslednje informacije preden odprete ovojnino:
TachoSil comes in sterile packages and therefore it is important:
TachoSil je sterilno pakiran in zato je pomembno, da:
• only to use undamaged packages which have not been opened (post-sterilisation is not possible). • to have a non-sterile person open the outer aluminium cover • to have a sterile person open the inner sterile package
• uporabite samo nepoškodovana pakiranja, ki niso bila odprta (ponovna sterilizacija ni možna). • nesterilna oseba odpre zunanjo aluminijasto ovojnino • sterilna oseba odpre stično sterilno ovojnino
Use TachoSil soon after opening the outer aluminium cover.
Uporabite TachoSil kmalu po odprtju zunanje aluminijaste ovojnine.
Use TachoSil immediately after opening the inner sterile package.
Uporabite TachoSil takoj po odprtju stične sterilne ovojnine.
Instructions Use the TachoSil sponge under sterile conditions only.
Navodila Gobico TachoSil uporabite samo v sterilnih pogojih.
Find out which sponge size is needed.
Ugotovite, katera velikost gobice je potrebna.
The size of the sponge depends on the size of the wound.
Velikost gobice je odvisna od velikosti rane.
But please note that the sponge should cover 1-2 cm beyond the margins of the wound.
Vendar bodite pozorni, da mora gobica da pokriti 1- 2 cm preko robov rane.
If more than one sponge is needed, the sponges should overlap.
Če uporabite več kot eno gobico, se morajo gobice prekrivati.
For smaller wounds, the sponge can be cut to the appropriate size and shaped if too large.
Za manjše rane in če je gobica prevelika, jo lahko obrežete in oblikujete na ustrezno velikost.
Wipe the wound surface gently before placing the sponge on the wound.
Preden gobico namestite na rano, jo morate nežno obrišite.
Strong (pulsating) bleeding should be stopped surgically.
Močno (pulzirajočo) krvavitev je potrebno ustaviti kirurško.
Open the inner sterile package and remove the sponge.
Odprite stično sterilno ovojnino in vzemite gobico.
Pre-moisten the sponge in saline solution and place it on the wound immediately (if the wound is completely wetted by blood and other fluids, there is no need to moisten the sponge before application).
Gobico predhodno navlažite s fiziološko raztopino in jo takoj namestite na rano (če je rana popolnoma vlažna od krvi ali drugih tekočin, gobice pred namestitvijo ni potrebno navlažiti).
Pre-moisten surgical instruments or gloves with a saline solution, if necessary.
Po potrebi s fiziološko raztopino predhodno navlažite kirurške instrumente ali rokavice.
TachoSil may stick to surgical instruments or gloves covered with blood.
TachoSil se lahko prime na kirurške instrumente in rokavice, na katerih je kri.
Place the yellow, active side of the sponge against the wound.
Na rano namestite rumeno, učinkovito stran gobice.
Hold down the sponge with a gentle pressure for 3-5 minutes.
Gobico nežno pritiskajte 3- 5 minut.
Use a moistened glove or a moist pad to keep the sponge in place.
Uporabite navlažene rokavice ali vlažno blazinico, da ostane gobica na mestu.
Remove the light pressure carefully after 3-5 minutes.
Nežni pritisk previdno popustite po 3- 5 minutah.
To make sure that the sponge does not cling to the moistened glove or swab, and loosens itself from the wound, the sponge can be held down at one end e. g. by using a pair of forceps.
Za zagotovitev, da se gobica na bo prijemala na navlažene rokavice ali blazinico, in da ne odstopi z rane, gobico lahko držite na mestu na enem koncu, npr. s parom klešč.
There is no residual product which needs to be removed, the entire sponge is dissolved (resorbed)!
Gobica se v celoti razpusti (resorbira), zato ni potrebno odstraniti nobenih ostankov zdravila!
It is strongly recommended that every time that TachoSil is administered to a patient, the name and batch number of the product are recorded in the order to maintain a link between the patient and the batch of the product.
Zelo priporočljivo je, da se pri vsaki uporabi TachoSila pri bolniku zabeležita ime in serijska številka zdravila, za ohranitev povezave med bolnikom in serijo zdravila.
Storage of TachoSil Do not store above 25°C.
Shranjevanje TachoSila Shranjujte pri temperaturi do 25 °C.
What is Tadalafil Lilly?
Kaj je zdravilo Tadalafil Lilly?
Tadalafil Lilly is a medicine containing the active substance tadalafil.
Tadalafil Lilly je zdravilo, ki vsebuje zdravilno učinkovino tadalafil.
It is available as yellow, almond-shaped tablets (20 mg).
Na voljo je v rumenih tabletah mandljaste oblike (20 mg).
This medicine is the same as Cialis, which is already authorised in the European Union (EU).
To zdravilo je enako zdravilu Cialis, ki je že odobreno v Evropski uniji (EU).
The company that makes Cialis has agreed that its scientific data can be used for Tadalafil Lilly.
Družba, ki izdeluje zdravilo Cialis, je privolila, da se znanstveni podatki o tem zdravilu lahko uporabijo tudi za zdravilo Tadalafil Lilly.
What is Tadalafil Lilly used for?
Za kaj se zdravilo Tadalafil Lilly uporablja?
Tadalafil Lilly is used to treat men with erectile dysfunction (sometimes called impotence) when they cannot get or keep a hard penis (erection) sufficient for satisfactory sexual activity.
Zdravilo Tadalafil Lilly se uporablja za zdravljenje erektilne disfunkcije (imenovane tudi impotenca) pri odraslih moških, kadar ne zmorejo doseči ali ohraniti takšne erekcije penisa, ki omogoča zadovoljivo spolno aktivnost.
For Tadalafil Lilly to be effective, sexual stimulation is required.
Za učinkovitost zdravila Tadalafil Lilly je potrebno spolno vzburjenje.
The recommended dose of tadalafil is 10 mg, taken with or without food, ‘ on demand’ at least 30 minutes before sexual activity.
Priporočen odmerek zdravila Tadalafil Lilly je 10 mg, ki se vzame s hrano ali brez nje „ po potrebi “ vsaj 30 minut pred spolno aktivnostjo.
The maximum recommended dosing frequency is once per day, but continuous daily use of 10 or 20 mg tadalafil is not recommended.
Odmerek se lahko poveča na 20 mg pri moških, ki se na 10 - miligramski odmerek ne odzivajo.
Patients with severe liver problems or kidney problems should not take more than 10 mg in one dose.
Bolniki z resnimi obolenji jeter ali ledvic naj ne jemljejo odmerkov večjih od 10 mg.
Once-a-day dosing is not recommended in patients with severe kidney problems, and should only be prescribed to patients with liver problems after a careful evaluation of the benefits and risks of taking the medicine.
Odmerjanje enkrat na dan ni priporočljivo za bolnike, ki imajo hude težave z ledvicami, pri bolnikih z obolenji jeter pa naj se predpiše šele po skrbnem ovrednotenju razmerja med koristmi in tveganji jemanja zdravila.
The active substance of Tadalafil Lilly, tadalafil, belongs to a group of medicines called ‘ phosphodiesterase type 5 (PDE5) inhibitors’.
Zdravilna učinkovina v zdravilu Tadalafil Lilly, tadalafil, spada v skupino zdravil, imenovanih „ zaviralci fosfodiesteraze tipa 5 (PDE5) “.
It works by blocking the phosphodiesterase enzyme, which normally breaks down a substance known as cyclic guanosine monophosphate (cGMP).
Deluje tako, da blokira encim fosfodiesteraze, ki normalno razgrajuje snov, znano kot ciklični guanozin monofosfat GMP (cGMP).